Printer Friendly

DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS

 /REPEATING FOR POINTS NEEDED/
 PARSIPPANY, N.J., March 4 /PRNewswire/ -- Deprenyl USA, Inc.


(NASDAQ: DUSA) reports that Phase I/IIA human clinical trials for ALA Photodynamic Therapy (PDT) cm?enced the week of Feb. 21 at the University of California, Irvine. The principal investigator is Dr. Gerald Weinstein, head of the Department of Dermatology at the university. The University of California, Irvine, is a renowned center for the investigation of advanced dermatology treatment techniques, such as photodynamic therapy.
 Three separate human trials are involved, totalling more than 100 patients. The purpose of the research is to determine the clinically effective dosages of drug and light required to treat actinic keratoses and psoriasis. These studies involve a variety of protocols contained in the company's Investigational New Drug (IND) submission to the FDA which became effective in January 1993.
 Deprenyl USA is a development stage company established to bring prescription pharmaceutical products to worldwide markets, initially in the United States and Canada and primarily in the field of photodynamic therapy.
 Common stock and warrants are traded on NASDAQ under the symbols DUSA and DUSAW. They also trade on the Toronto Stoca?nge under the symbols DPU and DPU.WT.
 -0- 3/4/93
 /CONTACT: Toronto Office: Geoffrey Shulman, MD, president & CEO, 416-537-1070, or fax, 416-537-0258; Joseph P. Castelli, vice president, 201-299-9070, or fax, 201-335-0372, both of Deprenyl USA; Jim Tolan, sr. vice president, or Nicholas Biro, partner, 708-498-2284, or fax, 708-498-3144, both of O'Connor Biro & Associates, for Deprenyl USA/
 (DUSA)


CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU:

LR -- NY024 -- 3276 03/05/93 02:20 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1993
Words:267
Previous Article:HANSEN NATURAL CORP. (HANS) ANNOUNCES EXTENSION OF CLASS A WARRANTS
Next Article:FEBRUARY SALES INCREASE 4.5 PERCENT FOR THE MAY DEPARTMENT STORES COMPANY
Topics:


Related Articles
DEPRENYL USA ANNOUNCES CONDITIONAL LISTING ON TORONTO STOCK EXCHANGE
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA REPORTS POSITIVE INDEPENDENT STUDY OF ITS PROPOSED TREATMENT FOR SKIN CANCERS AND OTHER DERMATOLOGICAL DISORDERS
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
DEPRENYL USA INC. GRANTS MEDICIS RIGHT TO FIRST REFUSAL TO MARKET IN THE U.S.; POTENTIAL BREAKTHROUGH DRUG FOR SKIN CANCER, PSORIASIS, AND WARTS
DEPRENYL USA'S EXPERIMENTAL DRUG HAS POTENTIAL AS 'TREATMENT OF CHOICE' FOR SKIN CANCERS, SAYS PRESIDENT; NAME CHANGED TO DUSA PHARMACEUTICALS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters